Pfenex And PATH Partner On Vaccines
Friday, October 10, 2014
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of high-value biosimilar therapeutics and difficult to manufacture proteins, today announced the initiation of a multi-product research program with PATH, a global health nonprofit organization, as part of an initiative to enhance production of vaccines.
“We are both pleased and honored to partner with a globally respected organization as PATH in their mission to develop and deliver health solutions for unmet medical needs,” stated Bertrand C. Liang, chief executive officer of Pfenex. “This project represents yet another example of how Pfenex’s experience in the area of complex protein development and manufacture can provide innovative solutions for global health, with a portfolio of antigens and adjuvants that have been difficult or impossible to express in other host systems or organisms facilitating vaccine development previously not possible.”
As part of a recent grant to PATH from the Bill & Melinda Gates Foundation to develop a model for enhancing the production of recombinant protein vaccines against two diseases that pose a high burden in low-resource countries, PATH is working with Pfenex on an initial pilot project for two important vaccine components. The first is a promising adjuvant, the double-mutant Escherichia coli heat-labile toxin (dmLT), used by PATH’s enteric vaccine initiative with several vaccine candidates under development. The second is a leading malaria transmission-blocking vaccine candidate, Pfs25, supported by PATH’s Malaria Vaccine Initiative.
Source: Benzinga (link opens in a new window)
- Categories
- Health Care